在患有慢性阻塞性肺病的患者中使用罗夫卢米拉斯特的长期安全性,这是一个跨国观察数据库队列研究
Edeltraut Garbe1, Fabian Hoti2, Tania Schink1
1Department Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
International journal of chronic obstructive pulmonary disease
|August 26, 2024
概括
在瑞典和挪威,在COPD患者中使用Roflumilast并没有增加死亡风险. 德国和美国略有增加,可能是由于混因素.
科学领域:
- 肺部医学 肺部医学
- 药物监督 药物监督 药物监督
- 流行病学 流行病学
背景情况:
- 慢性阻塞性肺病 (COPD) 和慢性支气管炎需要长期治疗策略.
- 罗夫米拉斯特是一种固-4抑制剂,用于治疗COPD.
- 了解罗米拉斯的长期安全性,特别是死亡率,对于临床实践至关重要.
研究的目的:
- 评估ROFLUMILAST在患有COPD或慢性支气管炎的患者的长期安全性.
- 评估不同国家的罗夫米拉斯特使用与5年全因死亡率之间的关联.
主要方法:
- 使用来自德国,挪威,瑞典和美国的电子医疗保健数据库进行回顾性队列研究.
- 包括年龄≥40岁的患者,以及与罗米拉斯暴露和未暴露个体的匹配队列.
- 倾向性得分匹配考虑了人口统计,COPD严重程度和并发症. 考克斯回归模型分析了5年全因死亡率.
主要成果:
- 分析了112,541名未暴露和23,239名暴露的患者.
- 在德国和美国",一直使用"罗夫卢米拉斯特与5年死亡风险的小幅增加有关 (HRs > 1).
- 相反,德国,挪威和瑞典的"当前使用"罗米拉斯特显示了5年死亡风险的降低 (HRs < 1).
结论:
- 在瑞典和挪威使用罗米拉斯特时没有观察到增加5年死亡风险.
- 德国和美国"常用"的死亡风险略有增加,可能归因于依指示的残留混.
- 目前使用罗米拉斯特与德国,挪威和瑞典的死亡率降低有关,需要进一步调查.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
190
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
190
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:19Antiasthma Drugs: Leukotriene Modifiers
259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
259
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K